The role of treatment duration in chemotherapy regimens for the treatment of malignant diseases

被引:0
|
作者
Trümper, L [1 ]
Pfreundschuh, M [1 ]
机构
[1] Univ Saarlandes Kliniken, D-66421 Homburg, Germany
关键词
chemotherapy; treatment duration; dose intensity; remission rate;
D O I
10.1007/PL00002312
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The treatment of malignant tumors consists in the optimal combination of the 4 modalities surgery, radiotherapy, chemotherapy, and immunotherapy. An important goal of clinical research is the development of the optimal application of each of these modalities. Method: This review of the literature focuses on the importance of the total treatment duration and dose intensity in the development of chemotherapy regimens. Three important malignant diseases will be examined as to thr: optimal application of systemic chemotherapy. Result and Conclusion: Tumor models with the resulting hypotheses and well-designed clinical trials will Lead to progress in the treatment of malignant tumors.
引用
收藏
页码:466 / 471
页数:10
相关论文
共 50 条
  • [41] Radium treatment of malignant and non-malignant diseases
    不详
    BRITISH MEDICAL JOURNAL, 1929, 1929 (02): : 551 - 552
  • [42] An Unresolved Issue in Rhabdomyosarcoma Treatment: The Duration of Chemotherapy
    Bisogno, G.
    Hawkins, D.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S389 - S390
  • [43] An unresolved issue in rhabdomyosarcoma treatment: The duration of chemotherapy
    Bisogno, Gianni
    Hawkins, Douglas S.
    PEDIATRIC BLOOD & CANCER, 2020, 67 (05)
  • [44] Optimal Duration of Treatment Regimens for H. pylori Eradication
    Yancey, Joseph
    Neamand-Cheney, Kari
    AMERICAN FAMILY PHYSICIAN, 2014, 90 (11) : 766 - 767
  • [47] COMPARATIVE TRIAL OF 2 TENIPOSIDE-BASED COMBINATION CHEMOTHERAPY REGIMENS FOR THE TREATMENT OF ADVANCED MALIGNANT-LYMPHOMAS
    OCONNELL, MJ
    ANDERSON, J
    MERRILL, JM
    BENNETT, JM
    GLICK, JH
    BERARD, CW
    NEIMAN, RS
    BRODOVSKY, HS
    CANCER TREATMENT REPORTS, 1982, 66 (12): : 2021 - 2025
  • [48] Treatment Pathways and Biomarker Testing in Malignant Melanoma: A Transformation in Treatment Regimens in European Countries
    von Bredow, Dorothea
    Kolb, Nikolaus
    Ehlken, Birgit
    Schmid, Nina
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 119 - 119
  • [49] Evaluation of an anthroposophic supportive treatment intervention (ASTI) in children with malignant diseases during intensive chemotherapy
    Seifert, Georg
    Henze, Guenter
    Calaminus, Gabriele
    vom Hoff-Heise, Claudia
    Schlodder, Dietrich
    Rieger, Sabine
    Felenda, Jennifer
    Beckmann, Christiane
    Hufnagel, Rebecca
    Semaca, Cristina
    Laengler, Alfred
    PHYTOMEDICINE, 2015, 22 : S18 - S18
  • [50] Treatment of myasthenia: role of corticosteroid and immunosuppressor regimens
    Gajdos, P
    PRESSE MEDICALE, 1999, 28 (11): : 587 - 589